reta and cagrilintide Reta/Cagri Blend – 12.5mg/2.5mg Retatrutide + Cagrilintide Dosage: Stack

Poor peptide storage Leaving reconstituted AOD 9604 at room temperature or in sunlight degrades it

The committee will evaluate DSIP for opioid withdrawal, chronic insomnia, and narcolepsy and consider it for the Section 503A Bulk Drug Substances List

KPV (--) , -- (-MSH),

Safety Considerations in Canine Subjects Available research suggests: Toxicity data: Limited long-term toxicology studies in dogs specifically Side effects: Research in rodents generally reports minimal adverse effects at studied doses Drug interactions: Potential interactions with other medications not well characterized Monitoring: No established protocols for monitoring dogs receiving BPC-157 The absence of comprehensive safety data in dogs represents a significant knowledge gap

Each mL contains Cyanocobalamin 1000 mcg, sodium chloride 9 mg and benzyl alcohol 0.015 mL in water for injection